Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Sabine E. Grimm; Debra Fayter; Bram L. T. Ramaekers; Svenja Petersohn; Rob Riemsma; Nigel Armstrong; Xavier Pouwels; Willem Witlox; Caro Noake; Gillian Worthy; Jos Kleijnen; Manuela A. Joore

doi:10.1007/s40273-019-00792-7

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Sabine E. Grimm^*, Debra Fayter, Bram L. T. Ramaekers, Svenja Petersohn, Rob Riemsma, Nigel Armstrong, Xavier Pouwels, Willem Witlox, Caro Noake, Gillian Worthy, Jos Kleijnen, Manuela A. Joore

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

Original language	English
Pages (from-to)	1195-1207
Number of pages	13
Journal	Pharmacoeconomics
Volume	37
Issue number	10
DOIs	https://doi.org/10.1007/s40273-019-00792-7
Publication status	Published - Oct 2019

Keywords

BRENTUXIMAB VEDOTIN
HEALTH
DESIGN

Access to Document

10.1007/s40273-019-00792-7

Cite this

Grimm, S. E., Fayter, D., Ramaekers, B. L. T., Petersohn, S., Riemsma, R., Armstrong, N., Pouwels, X., Witlox, W., Noake, C., Worthy, G., Kleijnen, J., & Joore, M. A. (2019). Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 37(10), 1195-1207. https://doi.org/10.1007/s40273-019-00792-7

Grimm, Sabine E. ; Fayter, Debra ; Ramaekers, Bram L. T. ; Petersohn, Svenja ; Riemsma, Rob ; Armstrong, Nigel ; Pouwels, Xavier ; Witlox, Willem ; Noake, Caro ; Worthy, Gillian ; Kleijnen, Jos ; Joore, Manuela A. / Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma : An Evidence Review Group Perspective of a NICE Single Technology Appraisal. In: Pharmacoeconomics. 2019 ; Vol. 37, No. 10. pp. 1195-1207.

@article{882bd767ae3d401e930e7a72905212d8,

title = "Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal",

keywords = "BRENTUXIMAB VEDOTIN, HEALTH, DESIGN",

author = "Grimm, {Sabine E.} and Debra Fayter and Ramaekers, {Bram L. T.} and Svenja Petersohn and Rob Riemsma and Nigel Armstrong and Xavier Pouwels and Willem Witlox and Caro Noake and Gillian Worthy and Jos Kleijnen and Joore, {Manuela A.}",

year = "2019",

month = oct,

doi = "10.1007/s40273-019-00792-7",

language = "English",

volume = "37",

pages = "1195--1207",

journal = "Pharmacoeconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

number = "10",

}

Grimm, SE, Fayter, D, Ramaekers, BLT , Petersohn, S, Riemsma, R, Armstrong, N, Pouwels, X, Witlox, W, Noake, C, Worthy, G, Kleijnen, J & Joore, MA 2019, 'Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal', Pharmacoeconomics, vol. 37, no. 10, pp. 1195-1207. https://doi.org/10.1007/s40273-019-00792-7

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma : An Evidence Review Group Perspective of a NICE Single Technology Appraisal. / Grimm, Sabine E.; Fayter, Debra; Ramaekers, Bram L. T.; Petersohn, Svenja; Riemsma, Rob; Armstrong, Nigel; Pouwels, Xavier; Witlox, Willem; Noake, Caro; Worthy, Gillian; Kleijnen, Jos ; Joore, Manuela A.

In: Pharmacoeconomics, Vol. 37, No. 10, 10.2019, p. 1195-1207.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma

T2 - An Evidence Review Group Perspective of a NICE Single Technology Appraisal

AU - Grimm, Sabine E.

AU - Fayter, Debra

AU - Ramaekers, Bram L. T.

AU - Petersohn, Svenja

AU - Riemsma, Rob

AU - Armstrong, Nigel

AU - Pouwels, Xavier

AU - Witlox, Willem

AU - Noake, Caro

AU - Worthy, Gillian

AU - Kleijnen, Jos

AU - Joore, Manuela A.

PY - 2019/10

Y1 - 2019/10

KW - BRENTUXIMAB VEDOTIN

KW - HEALTH

KW - DESIGN

U2 - 10.1007/s40273-019-00792-7

DO - 10.1007/s40273-019-00792-7

M3 - Review article

VL - 37

SP - 1195

EP - 1207

JO - Pharmacoeconomics

JF - Pharmacoeconomics

SN - 1170-7690

IS - 10

ER -